Celularity (NASDAQ:CELU) Rating Increased to Buy at WBB Securities

Key Points

• Celularity has been upgraded to a "buy" rating by WBB Securities, with a price target of $6.00, indicating a potential upside of 173.97% from its previous close.
• Shares of Celularity experienced a 3.8% increase during midday trading, reaching $2.19, while the company has a market capitalization of approximately $58.45 million.
• Despite the upgrade from WBB Securities, Wall Street Zen downgraded Celularity from "hold" to "sell," reflecting mixed sentiment among analysts about the stock.

Celularity (NASDAQ:CELU - Get Free Report) was upgraded by equities researchers at WBB Securities from a "hold" rating to a "buy" rating in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a $6.00 price target on the stock. WBB Securities' price target indicates a potential upside of 173.97% from the stock's previous close.

Separately, Wall Street Zen cut Celularity from a "hold" rating to a "sell" rating in a research note on Friday. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $6.00.

Celularity Stock Up 3.8%

Shares of NASDAQ:CELU traded up $0.08 during midday trading on Tuesday, reaching $2.19. The company had a trading volume of 127,418 shares, compared to its average volume of 168,485. The company has a debt-to-equity ratio of 4.07, a current ratio of 0.25 and a quick ratio of 0.19. The stock's fifty day moving average price is $3.00 and its 200-day moving average price is $2.18. The stock has a market capitalization of $58.45 million, a P/E ratio of -0.70 and a beta of 0.81. Celularity has a one year low of $1.00 and a one year high of $5.22.

Celularity (NASDAQ:CELU - Get Free Report) last issued its quarterly earnings results on Friday, August 29th. The company reported ($1.02) earnings per share (EPS) for the quarter. The company had revenue of $5.74 million during the quarter. Celularity had a negative return on equity of 459.57% and a negative net margin of 165.22%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Valmark Advisers Inc. bought a new position in Celularity during the second quarter valued at about $98,000. Two Sigma Investments LP bought a new position in Celularity during the fourth quarter valued at about $93,000. Bank of America Corp DE boosted its stake in Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock valued at $73,000 after buying an additional 35,023 shares in the last quarter. Acadian Asset Management LLC bought a new position in Celularity during the first quarter valued at about $34,000. Finally, XTX Topco Ltd boosted its stake in Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock valued at $42,000 after buying an additional 11,057 shares in the last quarter. 19.02% of the stock is owned by institutional investors and hedge funds.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.